Now live: Pro — the full 13F research suite for serious investorsSee pricing →
CHI Advisors LLC

Q1 2022 · 13F-HR

CHI Advisors LLCholdings as filed

Filed 2022-05-16 · accession 0001085146-22-002173

$235,165
Reported value
22
Positions
2022-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
74349U108PROMETHEUS BIOSCIENCES INC$59,85325.5%1,585,096CommonSOLE
760273102RPTXREPARE THERAPEUTICS INC$36,75515.6%2,581,097CommonSOLE
230031106CGEMCULLINAN ONCOLOGY INC$28,82412.3%2,753,047CommonSOLE
729139105PLRXPLIANT THERAPEUTICS INC$18,6297.92%2,657,457CommonSOLE
H9060V101VECTIVBIO HLDG AG$14,5276.18%3,084,310CommonSOLE
901384107TSVT*2SEVENTY BIO INC$13,9845.95%819,672CommonSOLE
68217N105OMEGA THERAPEUTICS INC$6,5892.80%1,055,882CommonSOLE
517125100LRMRLARIMAR THERAPEUTICS INC$6,1362.61%1,515,148CommonSOLE
35655L107FREELINE THERAPEUTICS HLDGS$5,4462.32%4,862,319CommonSOLE
49372L100KEZAR LIFE SCIENCES INC$5,2292.22%314,612CommonSOLE
45175G108IKENA ONCOLOGY INC$4,9702.11%814,755CommonSOLE
68236R103ONCORUS INC$4,3031.83%2,417,436CommonSOLE
00973J101AKOUOS INC$3,9721.69%836,120CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$3,8771.65%2,829,712CommonSOLE
68570P101ORCHARD THERAPEUTICS PLC$3,7791.61%5,307,751CommonSOLE
3621LQ109GTHXEURG1 THERAPEUTICS INC$3,7141.58%488,635CommonSOLE
45790W108INOZYME PHARMA INC$3,6491.55%892,057CommonSOLE
492327101KROSKEROS THERAPEUTICS INC$3,3841.44%62,229CommonSOLE
221015100CRVSCORVUS PHARMACEUTICALS INC$2,7931.19%1,703,137CommonSOLE
690469101OVIDOVID THERAPEUTICS INC$2,6781.14%852,888CommonSOLE
74019P108PRECISION BIOSCIENCES INC$1,8680.79%606,629CommonSOLE
78464A870XBISPDR SER TR$2060.09%222,500PUTSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.